Gingival inflammation
Conditions
Interventions
Challenge intervention: no oral hygiene for 2 weeks
Intervention: erythritol tablets
Sponsors
Prof. dr. J.R. Bausch
ACTA Dental Research B.V. (ADR)
Gustav Mahlerlaan 3004
1081 LA Amsterdam
The Netherlands
r.bausch@acta.nl
Eligibility
Inclusion criteria
Inclusion criteria: • Adult, ≥ 18 years - 55 year • Male and female • Classified as systemically healthy, assessed by medical questionnaire • Minimum of 20 natural teeth: first and second molars must be present • Having visited the dentist for a regular check-up within the last year and having finished the necessary treatment. • Willing and able to give written informed consent • Willing to consent to use their collected anonymous and coded body materials for further research
Exclusion criteria
Exclusion criteria: • Anyone presenting with a dental pocket probing depth ≥ 5mm with bleeding on probing and attachment loss ≥ 2 mm, Dutch Periodontal Screening Index score 3+/ 4 • >40% BOP • Overt dental caries • Smokers, definition non-smoker: <1 cigarette every day for at least one year • Removable partial dentures • Removable night guard • Oral and/or peri-oral piercings • Apparent oral lesions (aphthous ulcers excluded) • Presence of orthodontic banding (except for lingual retention wire) • Abuse of drugs/alcohol • ACTA dental student or ACTA professional • Participation in a clinical study within the previous 30 days General health and use of medication: • Self-reported pregnancy or breastfeeding • Use of antibiotics during the last 3 months • Need of antibiotic prophylaxis prior to dental treatment • Use of anti-inflammatory drugs on a regular basis • Evidence of any systemic disease or compromised health condition • Acute sinusitis • Severe oral- pharyngeal infections • Current disorders/disease resulting in (self-induced) vomiting • Reduced salivary flow due to pathological reasons (e.g. Sjögren syndrome) • Adverse medical history or long-term medication • Prescribed medication (except for contraceptives - birthcontrol pills)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbiological composition | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical, immunological and clinical effects | — |
Contacts
Public ContactW. Crielaard
Outcome results
None listed